2018 Chemotherapy Labelling 
pharmaphorum
AUGUST 4, 2021
The HDAC inhibitor was given an accelerated approval by the FDA as a second-line PTCL therapy on the strength of overall response data, but a phase 3 study comparing Istodax to first-line chemotherapy showed no improvement on progression-free survival (PFS).
pharmaphorum
AUGUST 4, 2022
The CRPC trial – KEYNOTE-921 – looked at the combination of Keytruda (pembrolizumab) with docetaxel in more than 1,000 patients who had not been treated with chemotherapy before, but who had seen disease progression despite earlier treatment with an anti-hormonal therapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 19, 2023
The development of novel radiotherapeutics ushered in a new era in targeted treatment 1 for cancer, with two separate radiotherapeutic approvals in Europe and the US, in 2018 and 2022. How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy?
Pharmaceutical Technology
MARCH 6, 2023
Patients in the US and EU with recurrent or metastatic nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell carcinoma (HNSCC), are mostly treated with a combination of chemotherapy agents in the frontline setting, such as cisplatin + gemcitabine. months for the chemotherapy arm (hazard ratio [HR]: 0.52).
pharmaphorum
JANUARY 5, 2021
Roche’s drug is already FDA-approved as a monotherapy and in combination with Avastin (bevacizumab) and chemotherapy for previously-untreated NSCLC with high PD-L1 expression.
pharmaphorum
APRIL 23, 2021
While some argued that GSK overpaid for Tesaro in 2018, at least the deal is bringing badly needed new drugs to market for the under-pressure UK pharma and its highly-paid research chief Hal Barron.
Pharmaceutical Technology
SEPTEMBER 23, 2022
The current standard of care for many cancers is cisplatin chemotherapy or platinum therapy. In 2018, the FDA had granted Pedmark a breakthrough orphan drug designation. These open-label, randomized clinical trials were done in patients under 18 years of age. Pedmark clinical trials.
Expert insights. Personalized for you.
98 
Let's personalize your content